ABIOMED to Hold Conference Call and Investor Web Cast On April 29, 2003.

Business Editors/Health/Medical Writers

DANVERS, Mass.--(BUSINESS WIRE)--April 17, 2003

ABIOMED, Inc. (Nasdaq:ABMD) announced today that it will hold a conference call and investor web cast for investors and analysts on Tuesday, April 29, 2003 beginning at 2:00 p.m. (EDT) to provide a status update, including summary overview of the initial AbioCor(R) clinical trial, and to respond to investors' questions.

The discussion, which is anticipated to last approximately 30 minutes, can be accessed via ABIOMED's web site at www.abiomed.com. Questions may be submitted in advance of the call by email to [e-mail].

Based in Danvers, Massachusetts, ABIOMED, Inc. (pronounced "AB'-EE-O-MED") is a leading developer, manufacturer and marketer of medical products designed to assist or replace the pumping function of the failing heart. The Company's AbioCor Implantable Replacement Heart is being evaluated in patients as part of an ongoing initial clinical trial conducted under an Investigational Device Exemption from the United States Food and Drug Administration. The AbioCor has not been approved for commercial distribution, and is not available for use or sale outside of the initial clinical trial. ABIOMED currently manufactures and sells the BVS(R), a heart assist device for the temporary support of all patients with failing but potentially recoverable hearts.